Patent intelligence · US
US 9675655
Compositions for the treatment of dermatological conditions, disorders or diseases
Compositions for the treatment of dermatological conditions, disorders or diseases
Patent details — US 9675655
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 13, 2017
- Expiration
- Jun 8, 2037
- Claims
- 5
- CPC classes
- A61K, A61K31/07, A61K31/23, A61K31/355
Quick answer
US 9675655 (Compositions for the treatment of dermatological conditions, disorders or diseases) is held by Veit Hoermann Gesellschaft Für Unternehmenskommunikation mbH. Status: granted. Granted Jun 13, 2017. Expires Jun 8, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/07, A61K31/23, A61K31/355, A61K31/59, A61K31/714
More from Veit Hoermann Gesellschaft Für Unternehmenskommunikation mbH
Related pharmaceutical patents in our USPTO index.
-
US 12415779
Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof
granted -
US 12391642
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12331026
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
granted -
US 12264167
Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors
granted -
US 12171741
2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12077506
Indane derivatives as hypoxia inducible factor-2(α) inhibitors
granted -
US 11939303
Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
granted -
US 11753366
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted
Frequently asked questions
What is US patent 9675655?
US 9675655 (Compositions for the treatment of dermatological conditions, disorders or diseases) is held by Veit Hoermann Gesellschaft Für Unternehmenskommunikation mbH. Status: granted. Granted Jun 13, 2017. Expires Jun 8, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9675655?
Veit Hoermann Gesellschaft Für Unternehmenskommunikation mbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.
When does US 9675655 expire?
Our index shows an expiration date of Jun 8, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.